Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.44 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162904 | 0.79 | DPP4 (0.40) | DPP4HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL21787534 | 0.79 | HMGCR (0.36) | HMGCRCHRM1TBXA2RADRA1ACTH | |
| SCHEMBL12227932 | 0.78 | NAALAD2 (0.36) | DPP4HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL409178 | 0.77 | — | — | |
| SCHEMBL2801536 | 0.77 | HMGCR (0.40) | HMGCRCHRM1TBXA2RADRA1ACTH | |
| SCHEMBL10412105 | 0.77 | TSHR (0.36) | HMGCRCHRM1TBXA2RADRA1ACTH | |
| SCHEMBL27847024 | 0.77 | KDM4E (0.44) | HMGCRCHRM1TBXA2RADRA1ACTH | |
| SCHEMBL41886 | 0.75 | — | — | |
| SCHEMBL1717828 | 0.75 | HMGCR (0.41) | DPP4HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL4400325 | 0.74 | KMT2A (0.50) | CYP2D6CYP2C19HIF1AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599663-B2 | Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation | VALITOR, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250213704-A1 | METHOD OF TREATING A CANCER WITH A MULTIVALENT PEPTIDE CONJUGATE | VALITOR INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20240293585-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC. | 2024-09-05 | — | — | US | disclosed |
| CN-114269323-B | Hydrophilic linkers for multivalent peptide conjugates | 瓦利托尔有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240197810-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2024-06-20 | — | — | US | disclosed |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2023-11-21 | — | — | US | disclosed |
| EP-3659591-B1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2023-09-07 | — | — | US | disclosed |
| US-11542450-B2 | Biological buffers with wide buffering ranges | TPAT IP LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | US | disclosed |
| US-20020077330-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-20 | — | — | US | disclosed |
| US-6403580-B1 | HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES, THE USE THEREOF FOR TREATING DISEASES, PARTICULARLY TUMORAL DISEASES, DISEASES OF THE LUNGS AND RESPIRATORY TRACT, AND THE PREPARATION THEREOF. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-11 | — | — | US | disclosed |
| US-H1893-H | REACTING A HALOKETONE COMPOUND OR SALT WITH AN OXIDOREDUCTASE ENZYME SUPPLYING MICROORGANISM OR OXIDOREDUCTASE ENZYME CONTAINING MATERIAL OBTAINED FROM THE MICROORGANISM, CATALYZES THE REDUCTION OF HALOKETONE TO FORM HALOHYDROXIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-03 | — | — | US | disclosed |
| US-5776933-A | Method of inhibiting protease | E. R. SQUIBB & SONS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5760036-A | ENZYME INHIBITORS OF RETROVIRAL PROTEASE FOR PREVENTION OF AIDS | E. R. SQUIBB & SONS, INC. (US) | 1998-06-02 | — | — | US | disclosed |
| US-5559256-A | Aminediol protease inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0580402-A2 | Aminediol protease inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1994-01-26 | — | — | EP | disclosed |
| EP-0223588-B1 | PROCESS FOR THE PREPARATION OF BETA-LACTAM COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-06-12 | — | — | EP | disclosed |
| EP-0223588-A1 | Process for the preparation of beta-lactam compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293585-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | ACP1, PHOSPHO1, PARG | DPP4 3343/4885HMGCR 3557/4885CHRM1 2785/4885 |
| US-12599663-B2 | Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation | CD44, ICAM1, CD40 | DPP4 1483/4885HMGCR 2899/4885CHRM1 3150/4885 |
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | DPP4 2537/4885HMGCR 2976/4885CHRM1 1413/4885 |
| US-11542450-B2 | Biological buffers with wide buffering ranges | PEF1, SLC7A1, PLPBP | DPP4 3895/4885HMGCR 4281/4885CHRM1 2714/4885 |
| US-20020077330-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NR3C2, CYP11B2 | DPP4 4379/4885HMGCR 319/4885CHRM1 109/4885 |
| US-20250213704-A1 | METHOD OF TREATING A CANCER WITH A MULTIVALENT PEPTIDE CONJUGATE | DNPEP, MSN, NGLY1 | DPP4 381/4885HMGCR 3743/4885CHRM1 4783/4885 |
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K19, MAP3K20 | DPP4 4640/4885HMGCR 4810/4885CHRM1 1924/4885 |
| US-20240197810-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | DPP4 2537/4885HMGCR 2976/4885CHRM1 1413/4885 |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | PHOSPHO1, MSN, ZW10 | DPP4 2537/4885HMGCR 2976/4885CHRM1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.